INTRODUCTION
The floating sustained release dosage forms present most of the characteristics of hydrophilic matrices and are known as "hydrodynamically balanced systems" ("HBS") since they are able to maintain their low apparent density, while the polymer hydrates and builds a gelled barrier at the outer surface. 1, 2 The drug is released progressively from the swollen matrix, as in the case of conventional hydrophilic matrices. These forms are expected to remain buoyant (3-4 hours) on the gastric contents without affecting the intrinsic rate of emptying because their bulk density is lower than that of the gastric contents. 1 Many results have demonstrated the validity of the concept of buoyancy in terms of prolonged gastric retention time of the floating forms, improved bioavailability of drugs and improved clinical situations.
These results also demonstrate that the presence of gastric content is needed to allow the proper achievement of the buoyancy retention principle. Among the different hydrocolloids recommended for floating form formulations, cellulose ether polymers are most popular, especially hydroxypropyl methylcelluloses. Fatty material with a bulk density lower than one may be added to the formulation to decrease the water intake rate and increase buoyancy time. 1 Bilayer tablet is new era for developing a combination of two or more active pharmaceutical ingredient in single dosage form, Promoting patient convenience and compliance. Two or more ingredients to be formulated together inspite of active having different physico-chemical characteristics (active incompatibility). Dual release tablet is a unit compressed tablet dosage form intended for oral application. It contains two layers in which one layer having conventional or immediate release part of single or multiple actives; another layer is sustained or controlled release part of single or multiple actives. They are also called as multi-layer matrix tablet. Bi-layer tablet is suitable for sequential release of two drugs in combination, separate two incompatible substances and also for sustained release tablet in which one layer is immediate release as initial dose and second layer is maintenance dose. Diltiazem is similar to other peripheral vasodilators. Diltiazem inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ioncontrol gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. 2  2  2  2  2  2  2  2   Talc  2  2  2  2  2  2  2  2 Total (mg) 300 300 300 300 300 300 300 300 
1,2

FORMULATION
Hardness
The resistance of tablets to breakage under the conditions of storage, transportation and handling before usage depends on its hardness. The hardness of tablet of each formulationwas measured by Monsanto hardness tester. 
Friability
Friability was measured by Roche friability tester. 10 tablets were kept in the friability tester and it was rotated at 25 rpm for 4 minutes. Initial and final weights were then recorded and friability was calculated by following formula. 2 Friability= Initial weight-Final weight/ Initial weight ×100
Weight variation test
To study weight variation, 20 tablets were taken and were weighed individually and the weight variation was calculated with the use of standard deviation weight values were reported in mg. 
In vitro drug release studies:
In Vitro drug release studies were performed using USP dissolution test apparatus (Type 2). The dissolution studies were performed in 900 ml of 1.2 pH dissolution medium which was stirred at 50 rpm at 37±0.5°C. 
Swelling index
Swelling index was done on the prepared tablet by using 200ml beaker containing 0.1NHCL.The Temperature maintained at 37 0 C .the tablets were tested for 12hrs.the -tablets were carefully removed using a small basket, and the weight of each tablet was determined. 
Buoyancy lag time
It is determined in order to assess the time taken by the dosage form to float on the top of the dissolution medium, after it is placed in the medium. The tablets were placed in a 100 ml glass beaker containing 0.1M HCL as per IP. The time required for the tablet to rise to the surface and float was determined as floating lag time. 
Floating time
Test for buoyancy is usually performed in Simulated Gastric Fluid maintained at 37 0 C. The time for which the dosage form continuously floats on the dissolution media is termed as floating time. 
Stability studies
The optimized formulation was charged for the accelerated stability studies according to ICH guidelines (40 ± 2ºC and 75 ± 5% RH) for a period of 3 months in a stability chamber. The optimized formulations were placed in USP type-I flint vials and hermetically closed with bromobutyl rubber plugs and sealed with aluminum caps. The samples were withdrawn at 30, 60 and 90 days and evaluated for the drug content and In Vitro drug release. 
